Active Ingredient History
Cediranib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adenocarcinoma (Phase 2)
Ascites (Phase 2)
Astrocytoma (Phase 1)
Bile Duct Neoplasms (Phase 2)
Biliary Tract Neoplasms (Phase 2/Phase 3)
Brain Neoplasms (Phase 2)
BRCA1 Protein (Phase 2)
Breast Neoplasms (Phase 2)
Breast Neoplasms, Male (Phase 2)
Burkitt Lymphoma (Phase 1)
Carcinoma (Phase 1)
Carcinoma, Endometrioid (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Verrucous (Phase 2)
Carcinosarcoma (Phase 2)
Cholangiocarcinoma (Phase 2)
Colonic Neoplasms (Phase 1)
Colorectal Neoplasms (Phase 3)
Endometrial Neoplasms (Phase 2)
Ependymoma (Phase 1)
Fallopian Tube Neoplasms (Phase 3)
Gallbladder Neoplasms (Phase 2)
Gastrointestinal Stromal Tumors (Phase 2)
Glioblastoma (Phase 3)
Glioma (Phase 1)
Gliosarcoma (Phase 2)
Hamartoma (Phase 3)
Head and Neck Neoplasms (Phase 1)
Hodgkin Disease (Phase 1)
Intraocular Lymphoma (Phase 1)
Leiomyosarcoma (Phase 2)
Leukemia (Phase 1)
Leukemia, Hairy Cell (Phase 1)
Leukemia, Large Granular Lymphocytic (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 1)
Leukemia, Myeloid, Acute (Phase 2)
Liver Diseases (Phase 1)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 1)
Lymphoma, B-Cell, Marginal Zone (Phase 1)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, Large-Cell, Anaplastic (Phase 1)
Lymphoma, Large-Cell, Immunoblastic (Phase 1)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1)
Lymphoma, T-Cell (Phase 1)
Lymphoma, T-Cell, Peripheral (Phase 1)
Lymphomatoid Granulomatosis (Phase 1)
Medulloblastoma (Phase 1)
Melanoma (Phase 2)
Meningioma (Phase 1)
Mesothelioma (Phase 2)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 1)
Nasopharyngeal Carcinoma (Phase 2)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Neoplasms, Germ Cell and Embryonal (Phase 1)
Neuroectodermal Tumors (Phase 1)
Neurofibroma (Phase 2)
Neurofibroma, Plexiform (Phase 2)
Neurofibromatosis 1 (Phase 2)
Oligodendroglioma (Phase 1)
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 2)
Pleural Effusion, Malignant (Phase 2)
Prostatic Neoplasms (Phase 2)
Rectal Neoplasms (Phase 1)
Rhabdoid Tumor (Phase 1)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Alveolar Soft Part (Phase 2)
Sezary Syndrome (Phase 1)
Small Cell Lung Carcinoma (Phase 2)
Spinal Cord Neoplasms (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 1)
Testicular Neoplasms (Phase 1)
Thyroid Neoplasms (Phase 1/Phase 2)
Tongue Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
Waldenstrom Macroglobulinemia (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue